Valisure Founder and CEO David Light presents an overview of the complexities of the manufacturing and distribution of the global drug supply and the impact COVID-19 is having now and likely to have in the near future.

Light also discusses Valisure’s recent findings around probable human carcinogen NDMA in the diabetes medication metformin.  Anyone looking to participate in Valisure’s large-scale, crowdsourced study of metformin should click here for more information.

Q&A Section: